In Vivo Circular RNA-based CAR-T Cell Engineering Service

The Potential of In Vivo Circular RNA-based CAR-T Engineering

As a potential tumor immunotherapy method, in vivo CAR therapy takes advantage of multiple advantages to solve the current traditional methods of preparing CAR-T ex vivo, such as more economical, more convenient production, and less toxicity. Non-viral lipid nanoparticles represent an important approach being explored for in vivo engineering. Circular RNA-based in vivo CAR-T engineering as a novel solution for tumor immunotherapy.

Fig.1 The crosstalk among circRNA, miRNA, and mRNA in hematological malignancies.¹

Our In Vivo Circular RNA-based CAR-T Cell Engineering Service

To boost the development of CAR-T therapy, Creative Biolabs has successfully established a cost-effective in vivo circular RNA-based CAR-T engineering service to satisfy the diverse demands of our global customers. Our in vivo circular RNA-based CAR-T engineering service combines novel technology to design circular RNA transcripts that drive protein expression with validated and unique LNP delivery solutions. We provide customized optimized circular RNA-LNPs which offer simplified production, improved stability, and superior yield to empower in vivo CAR-T engineering.

Fig.2 The mechanism of circRNAs in immunotherapy.²

What Will You Gain

Work With Creative Biolabs

In the field of in vivo CAR-T engineering, we are committed to developing new approaches to greatly enhance its effectiveness in cancer therapy. At the same time, we also provide the following related services:

• In Vivo IVT mRNA-based CAR-T Cell Engineering Service
• In Vivo Viral-based CAR-T Cell Engineering Service

Frequently Asked Questions

Q1. Is the non-viral approach more suitable for in vivo CAR-T engineering development?

A: Non-viral approaches may have the advantage of clearer regulatory pathways. While, given that CAR transcripts are diluted (and eventually lost) as cells divide, non-integrating approaches may not provide sustained clinical responses. Therefore, it is impossible to simply explain which approach is more suitable, and it needs to be selected according to special project requirements.

For more details about our in vivo circular RNA-based CAR-T engineering service, please don't hesitate to get in touch with us.

References

1. Zhou, Xiangxiang, et al. "The functions and clinical significance of circRNAs in hematological malignancies." Journal of hematology & oncology 13.1 (2020): 138.
2. Fang, Zhixiao, Chunjie Jiang, and Shengli Li. "The potential regulatory roles of circular RNAs in tumor immunology and immunotherapy." Frontiers in Immunology 11 (2021): 617583.